Strategic Signal
announced historical backfill · human reviewed

SS-AIDT-2025-0011 · Aug 22, 2025

Paige → Tempus

Paige's clinically annotated, de-identified pathology dataset of nearly seven million slides with associated clinical and molecular information, acquired with its AI applications.

healthData Asset AcquisitionResearch date Nov 18, 2026Page updated Nov 18, 2026By Mike Ye
PendingAI Data Asset Score
PendingTransaction Signal Score
Data ownerPaige
AI buyer / developerTempus
Asset stateEmbedded / Continuing
Corpusunknown

1. What happened

Acquisition adds a substantial annotated pathology-slide dataset and AI technology. Company acquisition price is not a price paid solely for data; asset-specific rights need strict-qualification review. The announcement describes acquisition of the operating business and dataset; no independently priced data asset or uniform sublicensing right is inferred.

2. Buyer / seller

Tempus is the AI buyer or model-development side. Paige owns or contributes the proprietary corpus.

3. Economics

Whole-company consideration of $81.25 million, predominantly Tempus common stock, plus assumption of the remaining Azure commitment. No allocation to data alone. Economics scope: Whole-company consideration of $81.25 million, predominantly Tempus common stock, plus assumption of the remaining Azure commitment. No allocation to data alone.. Strategic Signal has not estimated undisclosed consideration.

4. Proprietary data

Paige's clinically annotated, de-identified pathology dataset of nearly seven million slides with associated clinical and molecular information, acquired with its AI applications. Historical depth: The exact licensed or transferred historical window is not disclosed.. Refreshability: Ongoing refresh obligations and the exact delivered corpus are not disclosed..

5. Rights and restrictions

Use is bounded by the announced agreement; full contractual controls are not disclosed. Ownership: permitted through the announced company acquisition; underlying third-party data rights remain subject to their terms. Training: not disclosed. Post-training: not disclosed.

6. Why the data matters for AI

Tempus intends to use the acquired pathology data and technology in oncology foundation-model development. The underlying dataset-specific training and sublicensing contract terms are not disclosed. No recipient-accessible repeated context/intervention/outcome structure is established by this announcement.

7. Asset Score — Pending/100

Only documented AI use and bounded rights usability are assessed. Evidence for remaining comparative corpus or transaction factors is insufficient; coverage remains below the locked 70% threshold and no total score is published. Score coverage: 14%.

FactorWeightRating / 5Points
Uniqueness / scarcity12Unknown—
Historical depth8Unknown—
Decision → outcome richness13Unknown—
Decision Value Density13Unknown—
Real-world grounding10Unknown—
Domain economic value9Unknown—
Refreshability8Unknown—
Proprietary advantage9Unknown—
Model-learning usefulness103.57.0
Non-replicability4Unknown—
Rights usability432.4

8. Transaction Signal Score — Pending/100

Only documented AI use and bounded rights usability are assessed. Evidence for remaining comparative corpus or transaction factors is insufficient; coverage remains below the locked 70% threshold and no total score is published. Score coverage: 26%.

FactorWeightRating / 5Points
Disclosed economics16Unknown—
Clean price discovery16Unknown—
Separability of data consideration15Unknown—
Explicit training / model-improvement use1438.4
Clarity of rights purchased1237.2
Competing bids10Unknown—
Strategic buyer quality6Unknown—
Repeatability / precedent value6Unknown—
Independent model-uplift evidence5Unknown—

9. M&A / valuation implications

Analysis: this is evidence of a governed external-asset arrangement, not a standalone valuation comparable without separable economics.

10. Evidence boundary

Strict qualification rests on the defined external corpus and separately material licensed, research or acquired rights, rather than ordinary internal AI deployment. Company acquisition price is not a price paid solely for data; asset-specific rights need strict-qualification review. The announcement describes acquisition of the operating business and dataset; no independently priced data asset or uniform sublicensing right is inferred. Rights not expressly established remain not_disclosed. This historical addition is not a new November announcement.